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Abstract
Introduction Many innovative cardiopulmonary bypass (CPB)
systems have recently been proposed by the industry. With few
differences, they all share a philosophy based on priming volume
reduction, closed circuit with separation of the surgical field
suction, centrifugal pump, and biocompatible circuit and
oxygenator. These minimally invasive CPB (MICPB) systems are
intended to limit the deleterious effects of a conventional CPB.
However, no evidence exists with respect to their effectiveness
in improving the postoperative outcome in a large population of
patients. This study aimed to verify the clinical impact of an
MICPB in a large population of patients undergoing coronary
artery revascularization.
Methods We conducted a retrospective analysis of 1,663
patients treated with an MICPB. The control group
(conventional CPB) was extracted from a series of 2,877
patients according to a propensity score analysis.
Results Patients receiving an MICPB had a shorter intensive
care unit (ICU) stay, had lower peak postoperative serum
creatinine and bilirubin levels, and suffered less postoperative
blood loss. Within a multivariable model, MICPB is
independently associated with lower rates of atrial fibrillation
(odds ratio [OR] 0.83, 95% confidence interval [CI] 0.69 to
0.99) and ventricular arrhythmias (OR 0.45, 95% CI 0.28 to
0.73) and with higher rates of early discharge from the ICU (OR
1.31, 95% CI 1.06 to 1.6) and from the hospital (OR 1.46, 95%
CI 1.18 to 1.8). Hospital mortality did not differ between groups.
Conclusion MICPBs are associated with reduced morbidity.
However, these results will need to be confirmed in a large,
prospective, randomized, controlled trial.
Introduction
During the last decade, many attempts have been made to
reduce the deleterious effects of cardiopulmonary bypass
(CPB) in cardiac operations. Basically, these attempts have
focused on specific changes to the standard equipment and
management, acting on the nature of the materials composing
the CPB circuit and oxygenator, on the technical aspects of
the pump and the circuit, and on the priming volume and the
anticoagulation management.
Biocompatible materials of different types have been applied,
but the results of this strategy are still debated. In a large, mul-
ticenter, prospective, randomized trial, no impact on postoper-
ative outcome was found in low-risk patients undergoing
elective coronary artery bypass graft (CABG) surgery [1].
However, a similar study, which focused on high-risk patients,
demonstrated a better outcome in patients treated with
heparin-coated materials [2]. Reduction of systemic heparini-
zation coupled with the use of biocompatible materials seems
to limit some of the adverse effects of CPB [3-7]. New devel-
opments of coating systems for CPB materials have shown
promising results [8-10]. Many authors [10-12] have stressed
the negative action of open circuits (namely, of the reinfusion
of shed blood from the pericardium) and proposed the use of
closed circuits with separation of the surgical field suction
blood. Finally, the need for limiting the circuit size in order to
reduce the hemodilution degree has been thoroughly
addressed in recent years, and many authors [13-17] have
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demonstrated the deleterious effects of severe hemodilution
during CPB in terms of postoperative morbidity and mortality.
In response to the considerable amount of literature stressing
the possible impact of CPB technology on postoperative out-
come, the industry proposed new 'minimally invasive' CPB
(MICPB) systems. Despite differences in biocompatible treat-
ment used and other minor technical issues, these systems all
have some points in common: they (a) are closed, (b) are
treated with biocompatible coatings, (c) can be primed with a
reduced fluid volume, (d) include a centrifugal pump, and (e)
are equipped with systems for separation of the shed blood
from the circuit.
However, despite enthusiastic reports on the limited number
of patients treated with these MICPB systems [18-21], there
is no clear information about the real impact of these technol-
ogies on the postoperative outcome of patients undergoing a
cardiac operation. The present study aimed to determine the
effects of an MICPB strategy on the postoperative outcome of
a large population of patients undergoing CABG surgery.
Materials and methods
Study design
We conducted a retrospective study based on the Institutional
Database for Cardiac Surgery including all patients undergo-
ing CABG surgery at our institution from 1 January 2001
through 31 March 2006. The local ethical committee waived
the need for approval, and all patients gave written consent to
the scientific treatment of their data.
During the study period, we applied two distinct types of CPB
management. Some patients received our conventional treat-
ment based on a standard open circuit with roller or centrifugal
pumps, conventional anticoagulation management, no bio-
compatible treatment, and no separation of the pericardial
shed blood suction. These patients were considered the con-
ventional CPB group. Other patients received an MICPB
based on a closed circuit with separation of the pericardial
shed blood suction, a centrifugal pump, phosphorylcholine-
treated materials, and a reduction of systemic heparinization.
These patients comprised the MICPB group. During the study
period, no specific selection was carried out in assigning
patients to the control or the MICPB group, assignment to
groups was based only on the availability of the different CPB
circuits. The use and availability of MICPB circuit were homo-
geneous during the whole study period and without a time-
related bias. Closed circuits have been used for the last 10
years by all the perfusionists in our institution. Therefore, no
selection bias based on the experience of the operating room
team was expected.
Patient population
Four thousand five hundred and forty patients undergoing iso-
lated CABG operations were admitted to the study. Two thou-
sand eight hundred and seventy-seven comprised the
conventional CPB group, and 1,663 the MICPB group. Apply-
ing a propensity score analysis (see Statistics), we extracted a
control group of 1,663 patients from the conventional CPB
group.
Anesthesia, surgery, and CPB management
Premedication included atropine sulphate, prometazine, and
fentanyl. Anesthesia was induced with an intravenous infusion
of remifentanil and a midazolam bolus. Cisatracurium besylate
was later administered to allow tracheal intubation. Subse-
quently, the anesthesia was maintained with a continuous infu-
sion of remifentanil and midazolam.
CPB was established via a standard median sternotomy, aor-
tic root cannulation, and single-cannula atrial cannulation for
venous return. As requested by the surgeon, the lowest core
body temperature during CPB varied from 32°C to 37°C.
Antegrade intermittent cold crystalloid or cold blood cardio-
plegia was used according to the surgeon's preference. The
following equipment and techniques were applied in the con-
trol and MICPB groups:
In the control group, an open circuit with a hard-shell reservoir
receiving blood from the venous cannulation, an active venting
from the aortic root, and all the surgical field suctions were
directly sent to the venous reservoir. The circuit was primed
with 700 ml of a gelatin solution (Eufusin; Medacta Italia,
Milan, Italy) and 200 ml of trihydroxymethylaminomethane
solution. Roller (Stöckert, part of Sorin Group Deutschland
GmbH, München, Germany) or centrifugal (Medtronic, Inc.,
Minneapolis, MN, USA) pumps were used according to avail-
ability in the control group. The oxygenator was a hollow-fiber
D 905 Avant (Dideco, part of Sorin Group Italia S.r.l, Miran-
dola, Italy). The pump flow was targeted between 2.0 and 2.4
liters per minute per square meter and the target mean arterial
pressure was settled at 60 mm Hg.
Anticoagulation was established with an initial dose of 300 IU
per kilogram of body weight of porcine intestinal heparin
injected into a central venous line 10 minutes before the initi-
ation of CPB and with a target activated clotting time (ACT) of
480 seconds. At the end of CPB, heparin was reversed by
protamine chloride at a 1:1 ratio of the loading dose, regard-
less of the total heparin dosage.
In the MICPB group, a closed circuit with a collapsible venous
reservoir receiving blood from the venous cannulation and
from a gravity venting from the aortic root was applied, and
suction blood from the surgical field was actively drained into
a hard-shell reservoir and never readmitted to the systemic cir-
culation unless processed with a cell saver. All CPB surfaces
were treated with a biocompatible coating (phosphorylcho-
line). This system, which has been published by our group
[9,10], is manufactured on request by Dideco and is known asAvailable online http://ccforum.com/content/11/2/R45
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'intraoperative ECMO (extracorporeal membrane oxygena-
tion).' Anticoagulation was established with a target ACT of
300 seconds. The heparin loading dose was settled using the
Hepcon HMS (Medtronic, Inc.).
No difference between groups existed with respect to the
pump flow and pressure policy, the oxygenator, the priming
nature, and the protamine administration protocol. In both
groups, a cell saver was used throughout the surgical proce-
dure. Tranexamic acid (15 mg/kg before CPB and 15 mg/kg
after protamine) was used in all patients.
Data collection and definitions
Using the Institutional Database for Cardiac Surgery, which
follows the guidelines of the National Societies of Cardiotho-
racic Surgery and Cardiothoracic Anesthesia, we collected
and analyzed the following preoperative data: demographics
(age in years, gender, weight in kilograms, and height in cen-
timeters), preoperative cardiovascular profile (ejection frac-
tion, recent [30 days] myocardial infarction, unstable angina,
use of antiplatelet agents [salycilates or clopidogrel/ticlopi-
dine], congestive heart failure, previous vascular surgery, pre-
vious cardiac surgery, and use of intra-aortic balloon pump
[IABP]), presence of comorbidities (chronic renal failure, dia-
betes on medication, chronic obstructive pulmonary disease
[COPD], and cerebrovascular accident), and laboratory
assays (serum creatinine value in milligrams per deciliters,
serum bilirubin value in milligrams per deciliters, and hemat-
ocrit [HCT] percentage).
Operative data comprised primary operating surgeon, emer-
gency procedure, number of distal coronary anastomoses,
CPB duration in minutes, aortic cross-clamping duration in
minutes, priming volume in milliliters, type of cardioplegic solu-
tion (crystalloid versus blood), lowest temperature in degrees
Celsius, and lowest HCT percentage on CPB, total heparin
dose in international units, and total protamine dose in
milligrams.
Outcome variables included time on mechanical ventilation in
hours, intensive care unit (ICU) stay in days, postoperative
hospital stay in days, number of patients extubated early
(within six hours from arrival in the ICU), number of patients
discharged early from the ICU (the day after the operation),
number of patients discharged early from the hospital (within
five days from the surgical operation), peak postoperative
serum creatinine level in milligrams per deciliters, peak postop-
erative serum bilirubin level in milligrams per deciliters, postop-
erative bleeding in milliliters (during the first 12 hours from the
arrival to the ICU), surgical revision rate, need for homologous
blood transfusions, perioperative myocardial infarction rate
(new Q waves plus enzymatic criteria), low cardiac output syn-
drome (treated with inotropes or IABP), atrial fibrillation rate
(not pre-existing), presence of ventricular arrhythmias, acute
renal failure (requiring renal replacement therapy), stroke,
peripheral thromboembolism (lower limb ischemia diagnosed
on clinical plus echo-Doppler examination), severe pulmonary
dysfunction, cardiac arrest, sepsis, and hospital mortality rate.
Beginning in January 2004, a specific fast-track program
aimed at early discharge of patients from the ICU was applied.
This program includes specific criteria for extubation and dis-
charge from the ICU, which have been detailed in a recently
published article [22]. The presence of this program was
therefore included within the possible bias factors considered
in the propensity score analysis and in the multivariable
analysis.
Statistics
All data are expressed as mean ± standard deviation of the
mean or as absolute number and percentage when appropri-
ate. A p value of less than 0.05 was considered significant for
all statistical tests. The statistical analysis was performed
using SPSS 11.0 software (SPSS Inc., Chicago, IL, USA).
The composition of the control group was obtained by extract-
ing 1,663 patients from the conventional CPB group accord-
ing to the propensity score technique. The following approach
was applied:
Step 1
The conventional CPB group and MICPB group were com-
pared for significant differences in pre- and intra-operative var-
iables. Variables directly related to the different techniques
(priming volume, lowest HCT on CPB, and heparin and pro-
tamine doses) were excluded from the analysis. By means of
appropriate statistical tests (Student t test for unpaired data
and Pearson's χ2 test), 11 variables were found to be signifi-
cantly different between groups: age, male gender, weight,
ejection fraction, recent myocardial infarction, serum creati-
nine level, serum bilirubin level, COPD, cerebrovascular acci-
dent, diabetes on medication, and lowest temperature on
CPB. With the exception of serum creatinine level, all of the
comorbidities and risk factors were more frequent in the
MICPB group.
Step 2
The 11 variables were entered into a multivariable stepwise
forward logistic regression, and the use of MICPB was the
dependent variable. The final predictive model for MICPB use
included eight independent variables: weight (p = 0.002), age
(p < 0.001), recent myocardial infarction (p < 0.001), serum
creatinine level (p < 0.001), serum bilirubin level (p = 0.009),
cerebrovascular accident (p = 0.011), diabetes on medication
(p < 0.001), and lowest temperature on CPB (p = 0.031). On
the basis of the logistic regression equation, each patient
received a score (range, 0 to 1) that represented the 'propen-
sity score' for being treated with MICPB.Critical Care    Vol 11 No 2    Ranucci and Isgrò 
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Step 3
Patients in the MICPB group were divided into quintiles
according to their propensity score. The first quintile (propen-
sity score, 0 to 0.2) included 59 patients, the second (0.21 to
0.40) 848 patients, the third (0.41 to 0.60) 495 patients, the
fourth (0.61 to 0.80) 259 patients, and the fifth (0.81 to 1) 2
patients. According to this distribution, the same number of
patients for each quintile was randomly extracted from the
conventional CPB file, resulting in the control group. Homoge-
neity of the groups for pre- and intra-operative variables was
checked using a Student t test for unpaired data (between
means differences) and a Pearson's χ2 test (between frequen-
cies differences).
The distribution of primary operating surgeons was analyzed
for homogeneity between groups. During the study period,
2,727 patients (82%) were operated on by five surgeons, and
the remaining 599 by four other surgeons. We therefore con-
sidered six groups based on the operating surgeon. The distri-
bution did not differ significantly between the groups. The
number of patients treated with the fast-track protocol (from
January 2004) was 665 in the MICPB group and 632 in the
control group (not significantly different).
The outcome of the two groups was compared using a Stu-
dent t test for unpaired data (between means differences) and
a relative risk analysis (with 95% confidence intervals) for mor-
tality and for each specific morbid event. A multivariable logis-
tic regression analysis was applied to the main outcome
variables significantly associated with MICPB use in order to
investigate the role of MICPB as an independent predictor of
outcome within a model including other explanatory variables.
Results
The control group created through the propensity score tech-
nique was homogeneous with the MICPB group for all the pre-
operative variables and comorbidities (Table 1). The logistic
Euroscore did not differ significantly between the control (7.2
± 11.4) and the MICPB (7.5 ± 11.8) groups. Operative varia-
bles did not differ significantly between groups. Of course, as
a result of the different CPB techniques, patients in the MICPB
group had a significantly lower priming volume and conse-
quently a significantly higher nadir HCT value on CPB. As a
result of the different anticoagulation protocol, they received
significantly less heparin and protamine.
In the univariate analysis, the postoperative outcome (Table 2)
was affected by a higher morbidity in the control group.
Patients in this group experienced more postoperative bleed-
ing and had higher postoperative peak values of both serum
creatinine and bilirubin. MICPB significantly reduced the risk
for receiving an IABP and for atrial fibrillation, ventricular
arrhythmias, cardiac arrest, and peripheral thromboembolism.
Due to the reduced morbidity, patients treated with an MICPB
had a significantly shorter ICU stay, and the rates of patients
extubated early and discharged early from the ICU or the hos-
pital were significantly higher (1.5 to 2 times) in the MICPB
group. No significant difference was observed in terms of hos-
pital mortality.
The main outcome variables significantly associated with the
use of an MICPB system were analyzed using a multivariable
stepwise forward logistic regression analysis. After correction
for the other explanatory variables, MICPB remained inde-
pendently associated with a better outcome, with the excep-
tions of early extubation rate and postoperative IABP use
(Table 3).
Discussion
Since in the mid-1980s, many attempts to improve the quality
of CPB have been pursued. This trend toward a CPB improve-
ment, which led to the introduction of hollow-fiber oxygena-
tors, centrifugal pumps, and biocompatible treatments of the
circuit and oxygenator decreased considerably in the early
1990s due to the emerging off-pump coronary surgery. In
recent years, the new challenge has been to improve CPB
quality to the point of making this technique competitive even
with off-pump coronary surgery. Not by chance, during the last
five or six years, the market has been offering an overwhelming
number of new products (non-heparin-based biocompatible
treatments, new generation centrifugal pumps, and MICPB
equipment) aimed at improving the quality of CPB.
At present, at least three major companies are proposing an
'MICPB system.' With the exception of a few differences
related mainly to safety devices (aimed at detecting and
eliminating air entering the circuit), they share the same philos-
ophy: closed circuit, centrifugal pump, hollow-fiber oxygena-
tor, biocompatible surfaces, separation of the pericardial shed
blood suction, and reduced priming volume. Biocompatible
treatments of the circuit and oxygenator currently available on
the market differ in nature (heparin, phosphorylcholine, sul-
phate-sulphonate groups, and so on) but exert a well-estab-
lished action in limiting thrombin formation, platelet-count
decrease, and inflammatory reaction [3,5,8,9]. On a practical
basis, commercially available integrated MICPB systems
require a specific expertise, have a prolonged learning curve,
need team work, and are more expensive than conventional
circuits. Moreover, some concerns with respect to their safety
have been raised [23]. Therefore, their use is justified only if
their positive impact on postoperative outcome is well proven.
Unfortunately, this point is far from being clarified. Scientific
reports on the use of MICPB systems are limited, represented
mainly by case reports [20] or prospective trials enrolling lim-
ited numbers of patients [18,19]. The general feeling is good,
and various advantages have been reported: shorter ICU stay,
decreased need for inotropes, less myocardial injury, lower
rate of atrial fibrillation [18], and blunting of the inflammatory
reaction and of activation of the coagulation and fibrinolyticAvailable online http://ccforum.com/content/11/2/R45
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systems [19]. The main risk with these initial trials on new ther-
apeutic or technical systems is that patients in the study group
may receive better care and report improved outcomes merely
because they are being studied and received a new treatment;
this bias is quite common and is known as the Hawthorne
effect [24]. In a series of articles, Remadi and colleagues [25-
27] analyzed their experience with one of the commercially
available systems. In the first article [25], they basically
address the safety issues, practical feasibility, and general out-
come of patients treated with an MICPB system. Subse-
quently, they published a prospective randomized trial on 100
patients undergoing aortic valve surgery [26], where patients
treated with the MICPB had less neurologic events and a bet-
ter preservation of renal function but no differences in mortal-
ity. Finally, they recently published a prospective randomized
trial on 400 CABG patients [27], where the MICPB group
demonstrated a lower rate of low cardiac output syndromes,
need for allogeneic blood transfusions, and a better preserva-
tion of the renal function (lower peak values of creatinine and
urea); mortality was not significantly different between groups.
Table 1
Homogeneity of the groups for pre- and intra-operative variables
Variable Control group MICPB group P value
n = 1,663 n = 1,663
Age (years) 67.9 ± 9.5 67.9 ± 9.2 NS
Weight (kg) 73.5 ± 12 73.7 ± 14 NS
Height (cm) 167 ± 8.6 167 ± 9.8 NS
Ejection fraction 0.50 ± 0.11 0.50 ± 0.11 NS
Serum creatinine level (mg/dl) 1.31 ± 0.7 1.28 ± 0.8 NS
Serum bilirubin level (mg/dl) 0.63 ± 0.38 0.61 ± 0.36 NS
Hematocrit (percentage) 39.2 ± 4.6 39.2 ± 4.4 NS
Priming volume (ml) 874 ± 190 771 ± 134 0.001
CPB duration (minutes) 60.9 ± 25 59.8 ± 21 NS
Aortic cross-clamping time (minutes) 34.4 ± 13 34.6 ± 13 NS
Lowest hematocrit on CPB (percentage) 26.2 ± 3.9 27 ± 3.7 0.001
Lowest temperature on CPB (°C) 33 ± 1.6 32.9 ± 1.4 NS
Total heparin dose (IU) 26,733 ± 32,159 23,590 ± 30,421 0.004
Total protamine dose (mg) 221 ± 58 162 ± 58 0.001
Distal coronary anastomoses 3.26 ± 0.95 3.37 ± 0.98 NS
Gender male 1,311 (78%) 1,322 (79.5%) NS
Recent myocardial infarction 96 (5.8%) 107 (6.4%) NS
Unstable angina 240 (14.4%) 203 (12.2%) NS
Antiplatelet agents 350 (21%) 338 (20.3%) NS
Previous vascular surgery 93 (5.6%) 93 (5.6%) NS
Congestive heart failure 40 (2.4%) 38 (2.3%) NS
Preoperative IABP use 10 (0.6%) 11 (0.6%) NS
COPD 145 (8.7%) 151 (9.1%) NS
Cerebrovascular accident 104 (6.2%) 91 (5.5%) NS
Diabetes on medication 312 (18.7%) 344 (20.1%) NS
Chronic renal failure 40 (2.4%) 38 (2.3%) NS
Redo operation 45 (2.7%) 40 (2.4%) NS
Emergency procedure 13 (0.8%) 9 (0.5%) NS
CPB, cardiopulmonary bypass; COPD, chronic obstructive pulmonary disease; IABP, intra-aortic balloon pump; MICPB, minimally invasive 
cardiopulmonary bypass; NS, not significant.Critical Care    Vol 11 No 2    Ranucci and Isgrò 
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The present study represents by far the largest experience
with MICPB in CABG operations. The main strength of this
study is the patient population size: more than 3,200 patients
were analyzed. Conversely, the main limitation is that it is not
prospective and randomized, the control group having been
retrospectively created using a propensity score matching.
The main results of our study are that MICPB does not modify
mortality but exerts a considerable beneficial effect on postop-
erative morbidity. In this respect, our data are in agreement
with those of Remadi and colleagues [26,27], who could not
demonstrate different mortality rates in their prospective rand-
omized trials. In our study, myocardial function was not
addressed with specific markers; we saw a lower rate of
patients receiving IABP support in the MICPB group in the uni-
variate analysis, but this difference lost significance when cor-
rected for confounding factors. Other articles suggest a better
myocardial protection exerted by MICPB [18,27] and a better
hemodynamic profile [28], but we cannot confirm this on the
basis of our data. However, there are lower rates of atrial fibril-
lation, ventricular arrhythmias, and cardiac arrest. Atrial fibrilla-
tion after cardiac surgery may recognize an inflammatory
triggering mechanism [29-31], and there is evidence of blunt-
ing of the inflammatory reaction in patients treated with MICPB
[19] or when biocompatible circuits and separation of the
shed blood suction are applied [32]. We therefore are inclined
to attribute the atrial fibrillation containment to a better control
of the inflammatory reaction in MICPB patients, but we recog-
Table 2
Outcome variables in the two groups
Variable Control group MICPB group P value
n = 1,663 n = 1,663
Mechanical ventilation time (hours) 20.2 ± 79 17.3 ± 38 NS
ICU stay (days) 2.9 ± 4.3 2.5 ± 3.1 0.001
Postoperative hospital stay (days) 8.4 ± 5.9 8.1 ± 6.2 NS
Peak serum creatinine level (mg/dl) 1.43 ± 0.7 1.24 ± 1 0.001
Peak serum bilirubin level (mg/dl) 1.07 ± 0.79 0.89 ± 0.71 0.001
Bleeding (ml/12 hours) 505 ± 396 458 ± 342 0.001
Variable Count (percentage) Count (percentage) RR and 95% CI P value
Early extubation 139 (8.3) 197 (11.8) 1.47 (1.17–1.85) 0.001
Early ICU discharge 307 (18.4) 556 (33.4) 2.21 (1.89–2.6) 0.001
Early hospital discharge 187 (11.2) 316 (19) 1.85 (1.52–2.25) 0.001
Homologous blood transfusions 751 (45.1) 764 (45.9) 1.03 (0.9–1.18) NS
Surgical reoperation 79 (4.7) 64 (3.8) 0.8 (0.57–1.12) NS
Myocardial infarction 58 (3.5) 47 (2.8) 0.8 (0.54–1.19) NS
Major inotropic support 177 (10.6) 170 (10) 0.95 (0.76–1.19) NS
Intra-aortic balloon pump 49 (2.9) 28 (1.7) 0.56 (0.35–0.9) 0.015
Atrial fibrillation 293 (17.6) 251 (15.1) 0.83 (0.69–0.99) 0.049
Ventricular arrhythmias 59 (3.5) 26 (1.5) 0.43 (0.27–0.69) 0.001
Cardiac arrest 19 (1.1) 3 (0.2) 0.15 (0.04–0.53) 0.001
Acute renal failure 39 (2.3) 38 (2.3) 0.97 (0.62–1.53) NS
Stroke 10 (0.6) 14 (0.8) 1.4 (0.62–3.16) NS
Peripheral thromboembolism 6 (0.4) 0 (0) - 0.014
Severe lung dysfunction 22 (1.3) 14 (0.8) 0.63 (0.32–1.24) NS
Sepsis 10 (0.6) 14 (0.8) 1.4 (0.62–3.16) NS
Hospital mortality 55 (3.3) 50 (3) 0.9 (0.61–1.33) NS
CI, confidence interval; ICU, intensive care unit; MICPB, minimally invasive cardiopulmonary bypass; NS, not significant; RR, relative risk.Available online http://ccforum.com/content/11/2/R45
Page 7 of 9
(page number not for citation purposes)
nize that we have no information about the possible role of pro-
phylactic strategies (that is, perioperative beta-blocker use)
within our study group.
In agreement with other studies [26,27], we can confirm that
MICPB systems exert a protective effect on perioperative renal
function: the postoperative increase of serum creatinine was
lower in the MICPB group even if the rate of patients requiring
a dialytic treatment was not significantly different. Moreover,
the peak postoperative serum bilirubin is lower in MICPB
patients. Our MICPB has at least two characteristics that can
justify a beneficial effect on the renal side: it guarantees higher
HCT values during CPB and is equipped with biocompatible
surfaces. Limiting hemodilution during CPB decreases post-
operative renal dysfunction rate [13-17], and biocompatible
surfaces have been associated with a reduced rate of renal
dysfunction in high-risk patients [2].
Peripheral thromboembolic events are less frequent when the
MICPB is used. This can be attributed to the lower coagulation
system activation, thrombin generation [32], and the anti-
thrombin-saving effect already demonstrated with this tech-
nique [7]. However, we could not demonstrate that the overall
rate of thromboembolic events (including myocardial infarc-
tion, stroke, pulmonary embolism, and mesenteric infarction)
was lower in the MICPB group.
In our series, MICPB is associated with decreased postoper-
ative bleeding but not with a lower transfusion rate. This find-
ing is somewhat surprising, contradicting other studies [27]
and our own finding in a published study on a limited number
of patients [10]. However, we lack important information about
the amount of blood product administered and cannot rule out
that patients in the MICPB group may have received less
blood product. Moreover, the lower postoperative bleeding
detected is significant but clinically trivial (50 ml in 12 hours)
and therefore unlikely to determine differences in transfusion
rate. Finally, as a result of this better multifactorial outcome,
patients in the MICPB group had a shorter ICU stay and higher
rates of early ICU and hospital discharge.
Our MICPB system has some differences with respect to
other commercially available products. It is not preassembled,
and the venous return is not actively drained by a centrifugal
pump, but passively gravity-drained into a collapsible reservoir;
however, this difference does not result in a higher priming vol-
ume. In this respect, it is similar to the one proposed by Aldea
and colleagues [5,6,32]. In their experience, this group dem-
onstrated that a closed, heparin-bonded circuit with a reduc-
tion of systemic heparinization exerted a beneficial effect on
postoperative outcome [5], reducing blood loss and transfu-
sions, shortening mechanical ventilation time and ICU and
hospital stay, and reducing postoperative complications
(namely, thromboembolic events). The main characteristic of
our system is that, due to the presence of a collapsible venous
reservoir, no specific expertise or prolonged learning curve is
required of the perfusionist. Moreover, the risk of air entering
the circuit is not different from that of conventional open cir-
cuits, and no specific safety devices are required. Conversely,
the preassembled circuits available on the market are gener-
ally based on an active venous return with the inlet of the cen-
trifugal pump directly connected to the venous line. This
almost invariably leads to the risk of air entering the circuit.
Therefore, these circuits are equipped with bubble detectors
Table 3
Multivariable analysis (stepwise forward logistic regression) for MICPB impact on outcome variables
Outcome variable OR
(95% CI)
P value Adjusted for
Early extubation 1.34
(0.68–1.12)
0.27 Age, recent MI, serum creatinine value, fast-track program
Early ICU discharge 1.31
(1.06–1.6)
0.001 Gender, ejection fraction, serum creatinine value,
unstable angina, cerebrovascular accident,
CPB duration, fast-track program
Early hospital discharge 1.46
(1.18–1.8)
0.001 Gender, recent MI, serum creatinine value, 
chronic obstructive pulmonary disease, CPB duration,
lowest temperature on CPB, fast-track program
Postoperative intra-aortic balloon pump 0.7
(0.4–1.17)
0.17 Age, ejection fraction, recent MI, CPB duration,
lowest hematocrit on CPB
Atrial fibrillation 0.83
(0.69–0.99)
0.049 Gender, ejection fraction, preoperative hematocrit
Ventricular arrhythmias 0.45
(0.28–0.73)
0.001 Ejection fraction, serum creatinine value
Cardiac arrest 0.15
(0.04–0.5)
0.002 Congestive heart failure
CI, confidence interval; CPB, cardiopulmonary bypass; ICU, intensive care unit; MI, myocardial infarction; MICPB, minimally invasive 
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and automated clamps allowing air to be eliminated from the
circuit. Of course, this complex extracorporeal circuit needs a
specific expertise, and doubts about the safety of the tech-
nique have been raised [23].
Heparin dose reduction associated with MICPB is still an open
question. In the majority of studies published, the anticoagula-
tion protocol is not changed [18-21,25-27], whereas in our
study MICPB was associated with a reduced heparin dose.
Aldea and colleagues [5,6] demonstrated that this approach is
associated with a better outcome and does not induce
adverse events. Øvrum and colleagues [4], in an impressive
series of 5,658 patients, demonstrated that a strategy of
reduced heparinization plus heparin-bonded circuits led to a
postoperative outcome probably better than what was
reported in the literature for off-pump CABG patients.
We do not think that heparin dose reduction per se is respon-
sible for the better outcome of our MICPB patients. Simply,
because the thrombin generation with MICPB appears to be
reduced, less heparin is probably needed. Moreover, it is prob-
ably not useful to speculate which one of the single aspects
included in an MICPB strategy (closed circuit, biocompatible
surfaces, reduced hemodilution, heparin dose reduction, and
so on) is responsible for the better outcomes. MICPB should
be considered a multifactorial strategy, aimed to counteract
the multifactorial deleterious effects of a conventional CPB.
Within this model, further improvements to the MICPB can be
considered (for example, the use of specific soft-flow arterial
cannulas to reduce the traumatic effect exerted by high-veloc-
ity blood flow on the aortic wall). However, due to the absence
of active venting, the system that we are using at present is
inadequate for non-isolated CABG operations and for valvular
procedures. A possible improvement to the system is the use
of a closed venous reservoir actively draining the systemic
venous blood (by means of an external negative pressure)
which could be used for active venting of the left-sided cardiac
cavities.
With respect to previous studies that failed to demonstrate a
beneficial effect of heparin-coated, closed circuits, the main
difference was the use of a complete MICPB system, includ-
ing separation of the suction from the surgical field and a
reduced priming volume.
Conclusion
The use of MICPB in coronary patients undergoing surgical
revascularization is associated with an improvement in postop-
erative outcome. We did not find any difference in mortality,
but given that this figure was approximately 3%, the study was
probably underpowered in this respect. Even though our pop-
ulation was large and the selection bias was reduced by the
propensity score analysis, our results will need to be con-
firmed in a large, prospective, randomized, controlled trial.
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